Physician profile
Olufemi A Ogundeji
NPI 1912226697
$7,581.85
in general payments reported to CMS, 2019-2025
25 companies · $1,760 in 2025
The $1,760 reported for 2025 was more than what 87% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $426 · 2021: $1,349 · 2022: $684 · 2023: $1,692 · 2024: $1,062 · 2025: $1,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,501 · Education: $13.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,500.87 |
| Education | $13.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,105.94 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $920.89 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $798.03 | 2020-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lundbeck LLC | $739.08 | 2019-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $699.67 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $568.70 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $491.24 | 2020-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $422.79 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $339.43 | 2020-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $312.38 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $175.59 | 2021-2024 | Fanapt, Hetlioz |
| Indivior INC. | $167.52 | 2023-2024 | Perseris |
| Braeburn INC. | $147.55 | 2024-2025 | Brixadi |
| Ironshore Pharmaceuticals INC. | $128.98 | 2023-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $120.12 | 2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $102.41 | 2023 | Auvelity |
| Allergan, INC. | $101.44 | 2019-2020 | |
| Livanova USA, INC. | $76.24 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Bioxcel Therapeutics, INC. | $40.15 | 2024 | Igalmi |
| Corium, LLC | $34.15 | 2023 | Azstarys |
| Shire North American Group INC | $24.95 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.75 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.22 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $16.15 | 2021 | |
| Acadia Pharmaceuticals INC | $15.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olufemi Ogundeji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.